272 related articles for article (PubMed ID: 20842051)
1. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients.
Speiser DE; Schwarz K; Baumgaertner P; Manolova V; Devevre E; Sterry W; Walden P; Zippelius A; Conzett KB; Senti G; Voelter V; Cerottini JP; Guggisberg D; Willers J; Geldhof C; Romero P; Kündig T; Knuth A; Dummer R; Trefzer U; Bachmann MF
J Immunother; 2010 Oct; 33(8):848-58. PubMed ID: 20842051
[TBL] [Abstract][Full Text] [Related]
2. Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant.
Lienard D; Avril MF; Le Gal FA; Baumgaertner P; Vermeulen W; Blom A; Geldhof C; Rimoldi D; Pagliusi S; Romero P; Dietrich PY; Corvaia N; Speiser DE
J Immunother; 2009 Oct; 32(8):875-83. PubMed ID: 19752746
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
4. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
[TBL] [Abstract][Full Text] [Related]
5. HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells.
Chauvin JM; Larrieu P; Sarrabayrouse G; Prévost-Blondel A; Lengagne R; Desfrançois J; Labarrière N; Jotereau F
J Immunol; 2012 Mar; 188(5):2102-10. PubMed ID: 22291187
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.
Liénard D; Rimoldi D; Marchand M; Dietrich PY; van Baren N; Geldhof C; Batard P; Guillaume P; Ayyoub M; Pittet MJ; Zippelius A; Fleischhauer K; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2004 May; 4():4. PubMed ID: 15149168
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous coexpression of memory-related and effector-related genes by individual human CD8 T cells depends on antigen specificity and differentiation.
Gupta B; Iancu EM; Gannon PO; Wieckowski S; Baitsch L; Speiser DE; Rufer N
J Immunother; 2012 Jul; 35(6):488-501. PubMed ID: 22735807
[TBL] [Abstract][Full Text] [Related]
8. Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors.
Chapatte L; Colombetti S; Cerottini JC; Lévy F
Cancer Res; 2006 Jan; 66(2):1155-60. PubMed ID: 16424053
[TBL] [Abstract][Full Text] [Related]
9. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma.
Peterson AC; Harlin H; Gajewski TF
J Clin Oncol; 2003 Jun; 21(12):2342-8. PubMed ID: 12805336
[TBL] [Abstract][Full Text] [Related]
10. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L
Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905
[TBL] [Abstract][Full Text] [Related]
11. Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide.
Appay V; Speiser DE; Rufer N; Reynard S; Barbey C; Cerottini JC; Leyvraz S; Pinilla C; Romero P
Eur J Immunol; 2006 Jul; 36(7):1805-14. PubMed ID: 16761313
[TBL] [Abstract][Full Text] [Related]
12. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
13. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J
J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806
[TBL] [Abstract][Full Text] [Related]
14. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.
Baumgaertner P; Rufer N; Devevre E; Derre L; Rimoldi D; Geldhof C; Voelter V; Liénard D; Romero P; Speiser DE
Cancer Res; 2006 Feb; 66(4):1912-6. PubMed ID: 16488988
[TBL] [Abstract][Full Text] [Related]
16. Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients.
Laurent J; Speiser DE; Appay V; Touvrey C; Vicari M; Papaioannou A; Canellini G; Rimoldi D; Rufer N; Romero P; Leyvraz S; Voelter V
J Immunother; 2010 Sep; 33(7):723-34. PubMed ID: 20664354
[TBL] [Abstract][Full Text] [Related]
17. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202
[TBL] [Abstract][Full Text] [Related]
18. Tumor antigen-specific T-cells are Present in the CD8alphaalpha+ T-cell effector-memory pool.
Magalhaes I; Vudattu NK; Jäger E; Maeurer MJ
J Immunother; 2008; 31(9):840-8. PubMed ID: 18833003
[TBL] [Abstract][Full Text] [Related]
19. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.
Goldinger SM; Dummer R; Baumgaertner P; Mihic-Probst D; Schwarz K; Hammann-Haenni A; Willers J; Geldhof C; Prior JO; Kündig TM; Michielin O; Bachmann MF; Speiser DE
Eur J Immunol; 2012 Nov; 42(11):3049-61. PubMed ID: 22806397
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.
Smith JW; Walker EB; Fox BA; Haley D; Wisner KP; Doran T; Fisher B; Justice L; Wood W; Vetto J; Maecker H; Dols A; Meijer S; Hu HM; Romero P; Alvord WG; Urba WJ
J Clin Oncol; 2003 Apr; 21(8):1562-73. PubMed ID: 12697882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
